Surrozen, Inc. (SRZN)
Nasdaq · Healthcare · Biotechnology
$29.13−0.65%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $342M
- 52-week range
- $11.39 – $37.83
- 52-week change
- +111.85%
- EPS (trailing)
- −$38.80
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Revenue
- $3.5M (−67.37%)
- Net income
- −$242M
- Operating margin
- −1210.6%
- Diluted EPS
- −$32.37
- Free cash flow
- −$30.4M
From the company’s annual report on SEC EDGAR.
About Surrozen, Inc.
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc.
Headquarters: South San Francisco, United States · 44 employees · surrozen.com